The exclusive deal – which includes an upfront payment of $10 million and up to $340 million in milestone payments at the back end – covers the use of Selecta’s immunoglobulin G (IgG) protease drug IdeXork (Xork) alongside Astellas’ AT845, currently in the phase 1/2 FORTIS study in late-onset Pompe disease (LOPD) in adults.
Xork is designed as a pre-treatment to overcome one of the key limitations to adeno-associated virus (AAV) based gene therapies like AT845, namely that some patients have existing antibodies against the AAV vector that interfere with the treatment.
